Orexigen Therapeutics, Inc. is a biotechnology company focused on developing products for the treatment of obesity. The company’s marketed drug and key value-driver, Contrave, is a co-formulation of two well-established drugs, bupropion and naltrexone, in a sustained release (SR), formulation. The combination works to regulate appetite and energy expenditure through the central nervous system.

Portfolio Next